AR052060A1 - Suspensiones orales estables de azitromicina no dihidratada - Google Patents

Suspensiones orales estables de azitromicina no dihidratada

Info

Publication number
AR052060A1
AR052060A1 ARP050105334A ARP050105334A AR052060A1 AR 052060 A1 AR052060 A1 AR 052060A1 AR P050105334 A ARP050105334 A AR P050105334A AR P050105334 A ARP050105334 A AR P050105334A AR 052060 A1 AR052060 A1 AR 052060A1
Authority
AR
Argentina
Prior art keywords
azithromycin
oral suspensions
stable oral
oral suspension
conversion
Prior art date
Application number
ARP050105334A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR052060A1 publication Critical patent/AR052060A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un polvo para suspension oral, y a una suspension oral preparada a partir del mismo, que comprende azitromicina no dihidratada y un excipiente estabilizante de la conversion de azitromicina, en la que dicho excipiente reduce la conversion de la forma de azitromicina, cuando se pone en suspension, en otra forma de azitromicina. Adicionalmente, un procedimiento para reducir la conversion de una forma de azitromicina no dihidratada, en una suspension oral, incluyendo al menos una ciclodextrina en dicha suspension oral.
ARP050105334A 2004-12-21 2005-12-19 Suspensiones orales estables de azitromicina no dihidratada AR052060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63821804P 2004-12-21 2004-12-21

Publications (1)

Publication Number Publication Date
AR052060A1 true AR052060A1 (es) 2007-02-28

Family

ID=36602128

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105334A AR052060A1 (es) 2004-12-21 2005-12-19 Suspensiones orales estables de azitromicina no dihidratada

Country Status (7)

Country Link
US (1) US20100048498A1 (es)
EP (1) EP1830860A2 (es)
JP (1) JP2008524318A (es)
AR (1) AR052060A1 (es)
CA (1) CA2591744A1 (es)
TW (1) TW200633728A (es)
WO (1) WO2006067577A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI478915B (zh) 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
US20120101159A1 (en) * 2009-04-27 2012-04-26 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Ibuprofen lysinate oral suspension
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
RU2707748C2 (ru) * 2013-11-08 2019-11-29 Активус Фарма Ко., Лтд. Композиция водной суспензии, включающая наночастицы макролидных антибиотиков
JP6711875B2 (ja) * 2018-08-29 2020-06-17 日本食品化工株式会社 マクロライド化合物の苦味抑制剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
KR100603226B1 (ko) * 1998-11-30 2006-08-28 테바 파마슈티컬 인더스트리즈 리미티드 아지스로마이신의 에탄올레이트, 이의 제조 방법 및 약학 조성물
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE60232005D1 (de) * 2001-10-18 2009-05-28 Teva Pharma Stabilisierte azithromycin-zusammensetzungen
MXPA04005105A (es) * 2001-12-21 2004-08-19 Pfizer Prod Inc Formulaciones de acitromicina directamente compresibles.
GB0214277D0 (en) * 2002-06-20 2002-07-31 Biochemie Gmbh Organic compounds
GB0224197D0 (en) * 2002-10-17 2002-11-27 Biochemie Gmbh Organic compounds
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions

Also Published As

Publication number Publication date
JP2008524318A (ja) 2008-07-10
CA2591744A1 (en) 2006-06-29
WO2006067577A2 (en) 2006-06-29
US20100048498A1 (en) 2010-02-25
WO2006067577A3 (en) 2006-12-28
TW200633728A (en) 2006-10-01
EP1830860A2 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
USD629505S1 (en) Dry powder inhaler
CY1122066T1 (el) Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης εκλυσης που περιεχουν αμορφο cddo-me
EP1725191A4 (en) DYNAMIC SPACER FOR POSTERIOR OPERATION
AR074552A1 (es) Envase
PL1871277T3 (pl) Implant dentystyczny, elementy do połączenia z implantem dentystycznym oraz wewnętrzne połączenie pomiędzy implantem dentystycznym a każdym elementem
PL385565A1 (pl) Folie, wytwarzane z nich opakowania oraz sposoby stosowania
EP2042519A4 (en) MICROFIBRILLED CELLULOSE WITH CELLULOSE TYPE II CRYSTAL STRUCTURE AND FORM BODY CONTAINING MICROFIBRILLARY CELLULOSE
USD605810S1 (en) Lighting fixture
WO2009007979A3 (en) Encapsulated mesenchymal stem cells and uses thereof
AR052060A1 (es) Suspensiones orales estables de azitromicina no dihidratada
EP2251011A4 (en) SOLID PREPARATION FOR ORAL ADMINISTRATION
EP1662976A4 (en) THERMALLY MODIFIED MICROBIAL DERIVED CELLULOSE FOR IMPLANTATION I IN VIVO / I
EP2229822A3 (en) Food particle for promoting wellness
IL179884A0 (en) Fuel cells, micro-fuel cells and methods for the production thereof
JP2009504909A5 (es)
USD602707S1 (en) Hammock
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
AR059923A1 (es) Complemento nutricional para medio de fermentacion alcoholica
EP2116593A4 (en) METHOD FOR PRODUCING S-ADENOSYL-L-METHIONINE-CONTAINING DRY LEAF WITH EXCELLENT STORAGE STABILITY, PRODUCT MANUFACTURED BY THE METHOD AND SHAPED COMPOSITION OF DRY HEIGHT
WO2008067436A3 (en) Compounds and formulations suitable for radical scavenging
NO20063404L (no) Stabel med fibrose pads
NO20054604L (no) Malsokeenhet for utslipping pa dypt vann, saerlig i form av en node
AR044647A1 (es) Suspensiones orales estables de azitromicina en forma no dihidratada
EP1995332A4 (en) POROUS CRYSTALLINE GLUCID, METHOD FOR ITS PRODUCTION AND ITS USE
USD599321S1 (en) Digital translator

Legal Events

Date Code Title Description
FA Abandonment or withdrawal